Bachem Annual Report: What It Contains and How to Read It

The Bachem annual report is the yearly financial and corporate publication that Bachem Holding AG releases for each completed calendar year. It combines the Swiss peptide and oligonucleotide manufacturer's audited financial statements with management commentary, governance disclosures, and an outlook for the year ahead. Bachem posts the report on its investor relations page, normally at the same time as its full-year results announcement.

Bachem is not a US-listed company. Bachem Holding AG is headquartered in Bubendorf, Switzerland, and its shares trade on the SIX Swiss Exchange under the ticker BANB, so the annual report rather than a Form 10-K is the group's primary disclosure document.

What the Bachem annual report contains

The report follows a structure common to Swiss listed companies, and recent editions run well over a hundred pages. Core sections include:

• Letter to shareholders. In most editions the bachem ceo opens the document with a short review of the year's strategic and operational highlights.
• Management report. A narrative explanation of sales growth, margin development, capital investment, and the market environment for peptides and oligonucleotides.
• Corporate governance report. Board composition, committee structure, risk management, and internal control systems.
• Compensation report. Executive pay, the compensation system, and the related shareholder votes.
• Consolidated financial statements. Audited statements prepared under International Financial Reporting Standards (IFRS), covering the income statement, balance sheet, cash flow statement, and equity.
• Sustainability disclosures. Environmental, workforce, and supply chain metrics, which have expanded in recent editions.
• Auditor's report and parent company financial statements.

Bachem reports everything in Swiss francs (CHF). US readers who want dollar comparisons have to apply the exchange rate for the relevant period, because the report itself does not convert the figures.

When the Bachem annual report is published

Bachem's fiscal year matches the calendar year. Full-year results and the annual report typically appear in late February or March, and the Annual General Meeting follows in the spring, usually in April.

The report is one of several documents the group releases on a predictable schedule. Here is how they compare:

Document	Typical timing	What it covers
Full-year results media release	Late February to March	Headline sales, EBITDA, net income, and guidance for the new year
Annual report	Late February to March	Audited IFRS financial statements, management report, governance and compensation reports, sustainability data
Invitation to the Annual General Meeting	March to April	Agenda items, dividend proposal, board elections
Half-year report	July to August	Unaudited interim results for the first six months

The Bachem annual report contains audited figures, while the half-year report contains unaudited interim figures. That distinction matters when a number in one document appears to conflict with a number in the other.

Bachem annual report 2022

The Bachem annual report 2022 was released in early 2023 together with the group's 2022 full-year results. It covered a year in which Bachem reported roughly CHF 578 million in sales, sustained double-digit EBITDA margins, and continued investment in peptide manufacturing capacity.

That edition is still worth reading for two reasons. First, it captures the demand surge that followed the rapid growth of GLP-1 therapeutics, a theme that now runs through nearly every later report. The growing importance of bachem glp-1 manufacturing is visible in the capital expenditure figures from that year onward.

Second, the 2022 report establishes a baseline before a period of heavier spending and, later, softer ordering patterns as some customers worked through inventory. Anyone researching the bachem company can compare it side by side with more recent editions to see how guidance and backlog commentary evolved.

Verify exact figures in the official PDF instead of relying on summaries. Currency effects, restatements, and adjusted-versus-reported measures can all shift the headline numbers.

How to read the Bachem annual report like an analyst

A handful of numbers explain most of the story for a contract manufacturer like Bachem. Work through them in this order:

1. Group sales and local-currency growth. Swiss franc reporting can mask or exaggerate underlying momentum, so check both the reported and the currency-adjusted figure.
2. EBITDA margin. This shows whether volume growth is translating into operating leverage or being eaten by startup costs at new facilities.
3. Capital expenditure and capacity. Peptide and oligonucleotide plants are expensive and slow to build, so spending plans hint at management's view of demand three to five years out.
4. Order backlog and guidance. Forward-looking language is usually more informative than the prior year's results.
5. Cash flow. Operating cash flow against net income reveals how much growth is tied up in inventory and receivables.

None of this is investment advice, and figures in any single report should be weighed against a full financial picture. Speak with a licensed financial professional before acting on anything you read in a corporate filing.

Where to find the Bachem annual report and related resources

Download the PDF from the Investor Relations section of bachem.com, usually filed under Financial Reports or Publications. Older editions, including 2022, stay archived there, and printed copies can often be requested through the same page.

The site hosts more than financial filings. Laboratory customers frequently use the bachem peptide calculator for reconstitution and dilution math, and product pages list research-grade items such as CJC-1295 and ipamorelin. Those materials are sold for laboratory research use only and are not medicines.

For job seekers, hiring and workforce details appear in the report's personnel sections. If you are evaluating the company as an employer, the report's headcount and site investment data pair well with the openings listed under bachem careers.

If you are reading the report because you use peptides in a research or clinical setting, note that approved medicines and research chemicals follow very different rules. Anything intended for human use should be discussed with a qualified healthcare professional.

COMMON QUESTIONS

Frequently Asked Questions

When does Bachem publish its annual report?

Bachem publishes its annual report in late February or March, alongside the full-year results media release for the previous calendar year. Bachem's fiscal year matches the calendar year, and the Annual General Meeting follows in the spring, usually in April. The half-year report arrives separately in July or August.

Where can I find the Bachem annual report 2022?

The Bachem annual report 2022 is archived in the Investor Relations section of bachem.com, typically under Financial Reports or Publications. It was released in early 2023 with the 2022 full-year results and includes the audited consolidated financial statements, governance report, and the outlook for 2023. Printed copies can usually be requested through the same page.

What currency and accounting standard does Bachem use in its annual report?

Bachem reports in Swiss francs (CHF) under International Financial Reporting Standards (IFRS). The consolidated statements are audited by an independent external auditor, and the shares trade on the SIX Swiss Exchange under the ticker BANB. US readers who want dollar equivalents need to apply the exchange rate for the reporting period themselves.